Probiotics for Babies: What Pediatric Research Shows

The infant probiotic market has grown quickly. The pitch is that giving babies live bacteria helps their developing gut microbiome and improves health. The pediatric research has a few well-studied uses with real evidence — and a much larger pool of marketing claims that the evidence does not support. The two are worth keeping separate.

The Infant Microbiome

A baby's gut is essentially sterile at birth. It is then colonized by bacteria from the birth canal, the mother's skin, breast milk, and the environment. Babies born by C-section miss vaginal exposure and show different bacterial mixes in the gut for at least the first few years (Dominguez-Bello 2010 PMID 20566857). Breastfeeding is the strongest natural shaper of the early microbiome. Breast milk delivers human milk oligosaccharides (HMOs) that selectively feed Bifidobacterium species, especially B. infantis.

Infant Colic: The Strongest Evidence

The clearest pediatric probiotic evidence is for Lactobacillus reuteri DSM 17938 in colic. An individual-patient-data meta-analysis of four RCTs in 345 infants (Sung 2018 PMID 29279326) found that DSM 17938 roughly doubled the chance of treatment success (≥50% reduction in crying/fussing time at day 21) in breastfed infants. The benefit in formula-fed infants was much smaller and not statistically significant. For necrotizing enterocolitis (NEC) in preterm infants, a 2023 Cochrane review of 60 trials in over 11,000 infants found that probiotics reduced severe NEC and all-cause mortality (Sharif 2023 PMID 37196077), and several NICU programs now use specific multi-strain protocols. The American Academy of Pediatrics has stopped short of recommending universal NICU probiotics, citing variability in products and the FDA warning that followed the 2023 death of a preterm infant given a non-pharmaceutical-grade probiotic (FDA 2023 Safety Communication).

What the Evidence Does Not Support

Giving probiotics to all infants to "boost immunity" or "support development" is not supported by good evidence. Parents should be cautious about products that do not name a specific strain or cite infant clinical trials — the genus and species are not enough; the strain identifier (e.g., DSM 17938, BB-12, Bb-02) matters. Safety note: very premature infants (<32 weeks gestation), infants with central lines, and immunocompromised infants carry a small but real risk of probiotic sepsis. Use probiotics in those groups only under neonatal medical supervision and with a pharmaceutical-grade product.